196 related articles for article (PubMed ID: 19880909)
1. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis.
Daviskas E; Anderson SD; Jaques A; Charlton B
Chest; 2010 Apr; 137(4):861-8. PubMed ID: 19880909
[TBL] [Abstract][Full Text] [Related]
2. Inhaled mannitol improves lung function in cystic fibrosis.
Jaques A; Daviskas E; Turton JA; McKay K; Cooper P; Stirling RG; Robertson CF; Bye PTP; LeSouëf PN; Shadbolt B; Anderson SD; Charlton B
Chest; 2008 Jun; 133(6):1388-1396. PubMed ID: 18339790
[TBL] [Abstract][Full Text] [Related]
3. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.
Aitken ML; Bellon G; De Boeck K; Flume PA; Fox HG; Geller DE; Haarman EG; Hebestreit HU; Lapey A; Schou IM; Zuckerman JB; Charlton B;
Am J Respir Crit Care Med; 2012 Mar; 185(6):645-52. PubMed ID: 22198974
[TBL] [Abstract][Full Text] [Related]
4. Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial.
De Boeck K; Haarman E; Hull J; Lands LC; Moeller A; Munck A; Riethmüller J; Tiddens H; Volpi S; Leadbetter J; Charlton B; Malfroot A;
J Cyst Fibros; 2017 May; 16(3):380-387. PubMed ID: 28258928
[TBL] [Abstract][Full Text] [Related]
5. Sputum rheology changes in cystic fibrosis lung disease following two different types of physiotherapy: flutter vs autogenic drainage.
App EM; Kieselmann R; Reinhardt D; Lindemann H; Dasgupta B; King M; Brand P
Chest; 1998 Jul; 114(1):171-7. PubMed ID: 9674466
[TBL] [Abstract][Full Text] [Related]
6. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis.
Bilton D; Daviskas E; Anderson SD; Kolbe J; King G; Stirling RG; Thompson BR; Milne D; Charlton B;
Chest; 2013 Jul; 144(1):215-225. PubMed ID: 23429964
[TBL] [Abstract][Full Text] [Related]
7. Inhaled mannitol changes the sputum properties in asthmatics with mucus hypersecretion.
Daviskas E; Anderson SD; Young IH
Respirology; 2007 Sep; 12(5):683-91. PubMed ID: 17875056
[TBL] [Abstract][Full Text] [Related]
8. Effect of mannitol and repetitive coughing on the sputum properties in bronchiectasis.
Daviskas E; Anderson SD; Young IH
Respir Med; 2010 Mar; 104(3):371-7. PubMed ID: 19914814
[TBL] [Abstract][Full Text] [Related]
9. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study.
Bilton D; Robinson P; Cooper P; Gallagher CG; Kolbe J; Fox H; Jaques A; Charlton B;
Eur Respir J; 2011 Nov; 38(5):1071-80. PubMed ID: 21478216
[TBL] [Abstract][Full Text] [Related]
10. Mannitol dry powder for inhalation: in patients with cystic fibrosis.
Burness CB; Keating GM
Drugs; 2012 Jul; 72(10):1411-21. PubMed ID: 22755516
[TBL] [Abstract][Full Text] [Related]
11. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum.
Daviskas E; Anderson SD; Gomes K; Briffa P; Cochrane B; Chan HK; Young IH; Rubin BK
Respirology; 2005 Jan; 10(1):46-56. PubMed ID: 15691238
[TBL] [Abstract][Full Text] [Related]
12. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.
Bilton D; Tino G; Barker AF; Chambers DC; De Soyza A; Dupont LJ; O'Dochartaigh C; van Haren EH; Vidal LO; Welte T; Fox HG; Wu J; Charlton B;
Thorax; 2014 Dec; 69(12):1073-9. PubMed ID: 25246664
[TBL] [Abstract][Full Text] [Related]
13. Acute effects of combined exercise and oscillatory positive expiratory pressure therapy on sputum properties and lung diffusing capacity in cystic fibrosis: a randomized, controlled, crossover trial.
Radtke T; Böni L; Bohnacker P; Maggi-Beba M; Fischer P; Kriemler S; Benden C; Dressel H
BMC Pulm Med; 2018 Jun; 18(1):99. PubMed ID: 29898704
[TBL] [Abstract][Full Text] [Related]
14. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study.
Robinson M; Daviskas E; Eberl S; Baker J; Chan HK; Anderson SD; Bye PT
Eur Respir J; 1999 Sep; 14(3):678-85. PubMed ID: 10543292
[TBL] [Abstract][Full Text] [Related]
15. Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis.
Tarrant BJ; Le Maitre C; Romero L; Steward R; Button BM; Thompson BR; Holland AE
Respirology; 2017 Aug; 22(6):1084-1092. PubMed ID: 28397992
[TBL] [Abstract][Full Text] [Related]
16. Effect of inhaled dry powder mannitol on mucus and its clearance.
Daviskas E; Rubin BK
Expert Rev Respir Med; 2013 Feb; 7(1):65-75. PubMed ID: 23362816
[TBL] [Abstract][Full Text] [Related]
17. Effect of oral glycine on the clinical, spirometric and inflammatory status in subjects with cystic fibrosis: a pilot randomized trial.
Vargas MH; Del-Razo-Rodríguez R; López-García A; Lezana-Fernández JL; Chávez J; Furuya MEY; Marín-Santana JC
BMC Pulm Med; 2017 Dec; 17(1):206. PubMed ID: 29246256
[TBL] [Abstract][Full Text] [Related]
18. The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis.
Homnick DN; Marks JH; Rubin BK
J Aerosol Med; 2007; 20(1):45-9. PubMed ID: 17388752
[TBL] [Abstract][Full Text] [Related]
19. Pilot Randomized Controlled Trial Evaluating the Effect of Hypertonic Saline With and Without Hyaluronic Acid in Reducing Inflammation in Cystic Fibrosis.
Brivio A; Conese M; Gambazza S; Biffi A; Tirelli AS; Russo M; Foà M; Colombo C
J Aerosol Med Pulm Drug Deliv; 2016 Dec; 29(6):482-489. PubMed ID: 27149365
[TBL] [Abstract][Full Text] [Related]
20. Cystic Fibrosis Sputum Rheology Correlates With Both Acute and Longitudinal Changes in Lung Function.
Ma JT; Tang C; Kang L; Voynow JA; Rubin BK
Chest; 2018 Aug; 154(2):370-377. PubMed ID: 29559310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
